

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

**ISSUE OF NEW SHARES UNDER GENERAL MANDATE
PURSUANT TO THE SHARE AWARD SCHEME**

On 15 December 2020, the Board has resolved to allot and issue 30,000,000 new Shares to the Trustee under the General Mandate granted by the Shareholders at the AGM in order to grant awards to certain Selected Employees (the “**Proposed Grantees**”) pursuant to the Scheme.

The Company shall cause to pay the Trustee the total subscription price of US\$15,000, representing the nominal value of the Share multiplied by the number of new Shares to be allotted and issued pursuant to the General Mandate, from the Company’s resources to fund the Trustee to subscribe for the Awarded Shares.

The number of the Awarded Shares to be allotted and issued by the Company to the Trustee represents: (i) approximately 2.27% of the issued share capital of the Company as at the date of this announcement; and (ii) approximately 2.22% of the issued share capital of the Company as enlarged by the allotment of the Awarded Shares.

Reference is made to the announcement of IVD Medical Holding Limited (the “**Company**”) dated 19 May 2020 (the “**Announcement**”) relating to the adoption of the share award scheme by the Company on 19 May 2020 (the “**Scheme**”). Unless otherwise defined, capitalised terms used in this announcement shall bear the same meanings as those defined in the Announcement.

On 15 December 2020, the Board has resolved to allot and issue 30,000,000 new Shares to the Trustee under the General Mandate granted by the Shareholders at the AGM in order to grant awards to the Proposed Grantees pursuant to the Scheme. Pursuant to the General Mandate, the maximum number of Shares that can be allotted and issued by the Directors is 266,680,000 Shares. Save for the allotment of the Awarded Shares as disclosed in this announcement, no new Shares have been allotted or issued under the General Mandate as at the date of this announcement.

The Company shall cause to pay the Trustee the total subscription price of US\$15,000, representing the nominal value of the Share multiplied by the number of new Shares to be allotted and issued pursuant to the General Mandate, from the Company's resources to fund the Trustee to subscribe for the Awarded Shares and the Trustee shall hold such Awarded Shares for the Proposed Grantees, which shall be transferred to the Proposed Grantees at a consideration equivalent to the nominal value of the Share multiplied by the number of Shares to be granted to each of the Proposed Grantees under the Scheme, respectively, subject to the terms and conditions of the Scheme and fulfillment of all vesting conditions specified by the Board and in accordance with the vesting schedule (if any).

The Trustee is not a connected person (as defined under the Listing Rules) of the Company and is a third party independent of the Company. None of the Proposed Grantees is a Director or connected person (as defined under the Listing Rules) of the Company.

The number of the Awarded Shares to be allotted and issued by the Company to the Trustee represents: (i) approximately 2.27% of the issued share capital of the Company as at the date of this announcement; and (ii) approximately 2.22% of the issued share capital of the Company as enlarged by the issue and allotment of the Awarded Shares.

The Awarded Shares, when allotted and issued, shall rank pari passu among themselves and with the other Shares in issue. Pursuant to the Scheme, each of the Proposed Grantees shall not have any interest or rights (including the right to receive dividends) in the Awarded Shares allocated to him/her, prior to the vesting of the Awarded Shares granted to him/her. The Trustee, however, shall not exercise the voting rights in respect of any Shares held by it under the Trust (including but not limited to the Awarded Shares, any bonus Shares and scrip Shares derived therefrom).

Application will be made by the Company to the Stock Exchange for approval of the listing of, and permission to deal in, the Awarded Shares. Other than such approval to be granted by the Stock Exchange, the allotment of the Awarded Shares is not subject to any conditions or approval of the Shareholders.

Further information relating to the Awarded Shares is set out below:

Securities to be issued:	30,000,000 new Shares
Issue price(net):	The Awarded Shares shall be allotted and issued at nominal value of US\$0.0005 each Share
Funds to be raised:	Nil
	<i>Note: US\$15,000, which is the total nominal value of the Shares to be issued, shall be paid from the Company's resources to the Trustee</i>
Reasons for the issue:	To recognize the contributions by the Proposed Grantees and to give incentives in order to retain them for their continuing operation and development and to attract suitable personnel for further development of the Group
Identity of the allottee:	Bank of Communications Trustee Limited, being the Trustee appointed by the Company for the administration of the Scheme

Market price of the Awarded Shares:	HK\$1.96 per Share, being the closing price of the Shares as at 15 December 2020
Fund raising activity(ies) in the last 12 months:	The Company has not engaged in any fund raising activity(ies) by any issue of Shares in the 12 months immediately preceding the date of this announcement

DEFINITIONS

In this announcement, the following expressions shall (unless the context otherwise requires) have the following meanings:

“AGM”	the annual general meeting of the Company held on 3 June 2020
“Awarded Shares”	the 30,000,000 new Shares which will be allotted and issued to the Trustee under the General Mandate pursuant to the Scheme
“General Mandate”	a general unconditional mandate granted to the Directors at the AGM to allot, issue and deal with additional Shares in the capital of the Company of up to 20% of the aggregate number of issued Shares as at the date of the AGM, i.e. being 266,680,000 Shares

By order of the Board of
IVD Medical Holding Limited
Ho Kuk Sing
Chairman and Executive Director

Hong Kong, 15 December 2020

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, three non-executive Directors, namely, Mr. Chen Xingang, Mr. Yang Zhaoxu and Mr. Chan Kwok King, Kingsley and three independent non-executive Directors, namely, Mr. Lau Siu Ki, Mr. Zhong Renqian and Mr. Leung Ka Sing.